Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speaker : Prof. Jessica Lin

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr. Harish P ,Dr. Sai Vivek ,Dr. Ananth Pai ,Dr Vijay Agarwal

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

In this webinar, a detailed discussion is done on the front-line management of ALK-positive Lung Cancer.

Speakers : Dr Vijay Agarwal ,Dr. Ananth Pai ,Dr. Sai Vivek ,Dr. Harish P

Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2

Explore the impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, drawing insights from the pivotal PALOMA-2 study presented by Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

Discover the comprehensive impact of CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, with key insights from the PALOMA-2 study presented by Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

Explore the multifaceted advantages of CDK4/6 inhibitors in HR+/HER2- breast cancer, based on the PALOMA-2 study, in this insightful session with Dr. Bhavna Parikh.

Speakers : Dr Bhavna Parikh

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

A detailed discussion on the benefits of using CDK4/6 inhibitors in HR+/ HER2-aBC in clinical trials.

Speakers : Dr. Bhavna Parikh

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

The webinar gives insights into the role of pazopanib in managing renal cell carcinoma.

Speakers : Dr. Yogesh Kumar ,Dr. Pankaj Goyal ,Dr. Jatin Sarin ,Dr. Ankur Punia


Recommended News For You

Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer

Novel probes to label macrophages associated with cancer progression using a selective dye

GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.

PNH With Extravascular Hemolysis Approves Factor D Inhibitor.

Algorithm that predicts pancreatic cancer metastasis could help avoid unnecessary surgeries

A study suggests that you should disregard the "pack-years" when determining your eligibility for lung cancer screening.

It Is Cancer in Kate Middleton.

Recommended Articles For You

The Algorithmic Oncologist: A Comparative Clinical Review of AI in Predictive Cancer Planning 

Understanding Mean Corpuscular Volume: A Comprehensive Guide  

From Birthmarks to Tumors: The Science Behind Infantile Hemangioma  

Beyond Symptoms: The Predictive Promise of Targeted Radionuclide Therapy in Palliative Oncology 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.

2.

Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.

3.

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

4.

Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients

5.

When does a melanoma metastasize? Implications for management

1.

Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results

2.

The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies

3.

Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025

4.

Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked

5.

Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

3.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

4.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

5.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot